Oxford Cancer Analytics (OXcan) has secured $11m in Series A funding for the development of its liquid biopsy blood tests for ...

OXcan was founded in 2020 by Dr. Peter Jianrui Liu and Dr. Andreas Halner to advance early cancer detection using liquid biopsy.

Medtech Oxford Cancer Analytics (OXcan) said it has raised US$11m in Series A funding from global investors, including ...

In a study published today in the Journal of Clinical Investigation, Fred Hutch Cancer Center cancer chemical biologist ...

The blood test for those at high risk of lung cancer could lead to earlier detection and a "major reduction" in deaths, a ...

Oxford Cancer Analytics (OXcan), the medtech company developing blood tests for early cancer detection using advanced proteomics and AI, today announced it has raised US$11 million in Series A funding ...

This latest investment, which brings OXcan’s total funding to date to $16.7 million, will be used to develop and globally ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Biomarkers found in the blood can reveal changes in the body that may signal lung cancer before symptoms appear.

BALTIMORE and PALO ALTO, Calif., Jan. 8, 2025 /PRNewswire/ -- DELFI Diagnostics, Inc., developer of accessible blood-based, liquid biopsy tests that deliver a new way to enhance early cancer detection ...

Doctors around the world may soon have access to a new tool that could better predict whether individual cancer patients will ...

The Nodify CDT test measures levels of seven autoantibodies associated with lung cancer that can be detected in blood samples of patients with indeterminate lung nodules. Prior studies have ...